168 related articles for article (PubMed ID: 24906955)
21. First-trimester screening for fetal aneuploidy: biochemistry and nuchal translucency.
Orlandi F; Damiani G; Hallahan TW; Krantz DA; Macri JN
Ultrasound Obstet Gynecol; 1997 Dec; 10(6):381-6. PubMed ID: 9476320
[TBL] [Abstract][Full Text] [Related]
22. Correlations between maternal hepatitis B virus carrier status and Down's syndrome prenatal screening indicators and their effects on the screening results.
Huang L; Chen Y; Ning W; Chen Y; Yu D
J Obstet Gynaecol; 2022 Oct; 42(7):2793-2798. PubMed ID: 36036240
[TBL] [Abstract][Full Text] [Related]
23. The effect of a 'vanishing twin' on biochemical and ultrasound first trimester screening markers for Down's syndrome in pregnancies conceived by assisted reproductive technology.
Gjerris AC; Loft A; Pinborg A; Christiansen M; Tabor A
Hum Reprod; 2009 Jan; 24(1):55-62. PubMed ID: 18835870
[TBL] [Abstract][Full Text] [Related]
24. Screening for Down's syndrome: changes in marker levels and detection rates between first and second trimesters.
Berry E; Aitken DA; Crossley JA; Macri JN; Connor JM
Br J Obstet Gynaecol; 1997 Jul; 104(7):811-7. PubMed ID: 9236646
[TBL] [Abstract][Full Text] [Related]
25. Increased time-to-pregnancy and first trimester Down's syndrome screening.
Ranta JK; Raatikainen K; Romppanen J; Pulkki K; Heinonen S
Hum Reprod; 2010 Feb; 25(2):412-7. PubMed ID: 19945962
[TBL] [Abstract][Full Text] [Related]
26. Cross-trimester repeated measures testing for Down's syndrome screening: an assessment.
Wright D; Bradbury I; Malone F; D'Alton M; Summers A; Huang T; Ball S; Baker A; Nix B; Aitken D; Crossley J; Cuckle H; Spencer K
Health Technol Assess; 2010 Jul; 14(33):1-80. PubMed ID: 20624355
[TBL] [Abstract][Full Text] [Related]
27. Dimeric inhibin A as a marker for Down's syndrome in early pregnancy.
Aitken DA; Wallace EM; Crossley JA; Swanston IA; van Pareren Y; van Maarle M; Groome NP; Macri JN; Connor JM
N Engl J Med; 1996 May; 334(19):1231-6. PubMed ID: 8606718
[TBL] [Abstract][Full Text] [Related]
28. Serum screening for Down's syndrome between 8 and 14 weeks of pregnancy. International Prenatal Screening Research Group.
Wald NJ; George L; Smith D; Densem JW; Petterson K
Br J Obstet Gynaecol; 1996 May; 103(5):407-12. PubMed ID: 8624312
[TBL] [Abstract][Full Text] [Related]
29. [Evaluation of a programme for the prenatal screening for Down's syndrome by ultrasonographic nuchal translucency measurement and serum determinations in the first trimester of pregnancy].
Go AT; Hupkes HW; Lomecky M; Twisk J; Blankenstein JM; van Vugt JM
Ned Tijdschr Geneeskd; 2005 Dec; 149(50):2795-9. PubMed ID: 16385832
[TBL] [Abstract][Full Text] [Related]
30. First trimester Down's syndrome screening marker values and cigarette smoking: new data and a meta-analysis on free beta human chorionic gonadotophin, pregnancy-associated plasma protein-A and nuchal translucency.
Bestwick JP; Huttly WJ; Wald NJ
J Med Screen; 2008; 15(4):204-6. PubMed ID: 19106261
[TBL] [Abstract][Full Text] [Related]
31. Screening for trisomy 21 by fetal tricuspid regurgitation, nuchal translucency and maternal serum free beta-hCG and PAPP-A at 11 + 0 to 13 + 6 weeks.
Falcon O; Auer M; Gerovassili A; Spencer K; Nicolaides KH
Ultrasound Obstet Gynecol; 2006 Feb; 27(2):151-5. PubMed ID: 16388509
[TBL] [Abstract][Full Text] [Related]
32. If nuchal translucency screening is combined with first-trimester serum screening the need for fetal karyotyping decreases.
Marsk A; Grunewald C; Saltvedt S; Valentin L; Almström H
Acta Obstet Gynecol Scand; 2006; 85(5):534-8. PubMed ID: 16752230
[TBL] [Abstract][Full Text] [Related]
33. Urine tests for Down's syndrome screening.
Alldred SK; Guo B; Takwoingi Y; Pennant M; Wisniewski S; Deeks JJ; Neilson JP; Alfirevic Z
Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD011984. PubMed ID: 26662198
[TBL] [Abstract][Full Text] [Related]
34. The clinical usefulness of biochemical (free β-hCg, PaPP-a) and ultrasound (nuchal translucency) parameters in prenatal screening of trisomy 21 in the first trimester of pregnancy.
Ziolkowska K; Dydowicz P; Sobkowski M; Tobola-Wrobel K; Wysocka E; Pietryga M
Ginekol Pol; 2019; 90(3):161-166. PubMed ID: 30950006
[TBL] [Abstract][Full Text] [Related]
35. Second trimester prenatal screening for Down's syndrome in Mainland Chinese subjects using double-marker analysis of α-fetoprotein and β-human chorionic gonadotropin combined with measurement of nuchal fold thickness.
Liu F; Liang H; Jiang X; Zhang Y; Xue L; Yang C; Cheng J; Liu P; Liu Y; Guo X
Ann Acad Med Singap; 2011 Jul; 40(7):315-8. PubMed ID: 21870022
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of first trimester maternal serum and ultrasound screening for Down's syndrome in Eastern and Northern Finland.
Niemimaa M; Suonpää M; Perheentupa A; Seppälä M; Heinonen S; Laitinen P; Ruokonen A; Ryynänen M
Eur J Hum Genet; 2001 Jun; 9(6):404-8. PubMed ID: 11436120
[TBL] [Abstract][Full Text] [Related]
37. A screening program for trisomy 21 at 10-14 weeks using fetal nuchal translucency, maternal serum free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
Spencer K; Souter V; Tul N; Snijders R; Nicolaides KH
Ultrasound Obstet Gynecol; 1999 Apr; 13(4):231-7. PubMed ID: 10341399
[TBL] [Abstract][Full Text] [Related]
38. [Screening by maternal serum markers for Down's syndrome].
Liu JT; Hao N; Sun NH; Wang FY; Xu YH; Gai MY; Bian XM; Yang JQ
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2003 Apr; 25(2):156-9. PubMed ID: 12905710
[TBL] [Abstract][Full Text] [Related]
39. [Evaluation of pregnancy-associated plasma protein A (PAPP-A) and free beta subunit of human chorionic gonadotropin (beta hCG) levels and sonographic assesement of fetal nuchal translucency (NT) in singleton pregnancies between 11 and 14 weeks of gestation--Polish multi-centre research].
Borowski D; Czuba B; Cnota W; Hincz P; Czekierdowski A; Gajewska J; Jaczyńska R; Ceran A; Włoch A; Wyrwas D; Wiełgoś M; Szymusik I; Szaflik K; Sodowski K
Ginekol Pol; 2007 May; 78(5):384-7. PubMed ID: 17867331
[TBL] [Abstract][Full Text] [Related]
40. Comparison of serum markers in first-trimester down syndrome screening.
Canick JA; Lambert-Messerlian GM; Palomaki GE; Neveux LM; Malone FD; Ball RH; Nyberg DA; Comstock CH; Bukowski R; Saade GR; Berkowitz RL; Dar P; Dugoff L; Craigo SD; Timor-Tritsch IE; Carr SR; Wolfe HM; D'Alton ME;
Obstet Gynecol; 2006 Nov; 108(5):1192-9. PubMed ID: 17077242
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
